当前位置：   首页 > 需求大厅

 >  生产研发 

需求内容：由透明质酸均属于多糖类物质，应用该原料交联合成的水凝胶可避免异基因蛋白组分的凝胶带来的免疫学疑虑，部分厂家透明质酸凝胶产品吸水性强，与皮肤组织相容性好，可塑性强，可以根据不同需要塑性。 技术指标： 1. 体内停留时间可达到6个月以上 2. 有较好的细胞相容性、组织相容性 3. 可用于颜面部注射 4. 颗粒度均一，并可根据需要调节生产不同颗粒度的凝胶 5. 生产成本在200元/毫升以下 6. 1年内可获SFDA批准用于临床试验（含已获SFDA批准）   [更多]

罕见癌症研究基金会(RCRF),致力于通过战略投资和创新合作进行基础治疗罕见的癌症,和美国文化募捐组织(ATCC),世界上最大的非营利性细胞株库,建立神经内分泌肿瘤细胞株收集目录。肠道良性肿瘤和胰腺神经内分泌肿瘤(PNET)需求一种新疗法的研究和发展，即在体内原发性肿瘤中建立新的细胞株。 为了刺激发展新的良性肿瘤和PNET细胞系,该基金会是高兴地宣布第二次开放竞争十个人奖项:开发人员的第一个新的细胞系在每个疾病(肠道良性肿瘤和PNET)将获得100000美元，开发者的第二,第三,第四,第五个新细胞系在每个疾病将会收到50000美元。原文如下：https://www.innocentive.com/ar/challenge/9933756 The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Caring for Carcinoid Foundation therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery. Source: InnoCentive Challenge ID: 9933756 Challenge Overview This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use. To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual   [更多]

两个药品试行标准转正，要求100%通过，寻求代理，非诚勿扰。   [更多]

本公司因项目需要，对外委托基因毒性杂质研究：肼基、叠氮、氯代烷烃、酰氯类、氰化物等；请有研究能力的公司与我们联系。 项目要求： 1、完成以上基因毒性杂质的方法学开发、验证资料； 2、研究机构具有与实验相匹配的设备，并经过验证； 3、受委托机构可以接受审计及研制现场核查； 4、研究资料符合数据完整性要求；   [更多]

品种1：抗肿瘤类，50ml西林瓶 品种2：抗生素类，5ml西林瓶 品种3：抗生素类，10ml西林瓶 以上3个品种均为冻干粉针，我公司需要寻找冻干车间，制备3批中试样品（3批注册批），主要服务是提供中试生产场地及协助我们进行中试3批生产。希望能提供服务的公司与我联系，服务价格我预估在10万左右（每个品种10万，只是我个人预估的），实际成交价格可以面谈。   [更多]

排行世界的第五大的制药公司寻找合作伙伴，要求提供多种大环结构药物与合成技术，寻找有关大环领域的新药发现。希望此公司提供化学详细的3 d模型。具体请链接：https://www.innocentive.com/ar/challenge/9933642 The Seeker, a top-five big pharma company, is looking for collaboration partners with expertise in the area of macrocycle drug discovery. Specifically, three key areas are of interest: Chemistry partners with access to diverse macrocyclic structures & synthetic expertise In-silico chemistry partners with access to high-throughput 3-D models suitable for macrocycles In-vitro ADME experts with access to membrane systems, beyond PAMPA and Caco-2 This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (about 2–4 pages including contact information) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, the Seeker may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the time frame agreed upon.   [更多]

弥漫性大B细胞淋巴瘤(DLBCL)是一种最常见的非霍奇金淋巴瘤，诊断病例在美国约占淋巴瘤的30%。它是一种特异质性疾病。由于临床多样性和复杂性,又有新的突变在某些难治性患者身上被发现。阿斯利康需要创建一种弥漫性巨大B细胞淋巴瘤的合适的临床模型。 具体链接在：https://www.innocentive.com/ar/challenge/9933016 AstraZeneca Challenge: Developing Clinically-Relevant Models for Diffuse Large B Cell Lymphoma (DLCBL) TAGS: AstraZeneca, Physical Sciences, Life Sciences, Nature, Requests for Partners and Suppliers, Chemistry, RTP AWARD: See details | DEADLINE: 6/02/15 | ACTIVE SOLVERS: 9 | POSTED: 3/04/15 Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and accounts for up to 30% of newly diagnosed cases in the United States. It is a heterogeneous disease which in part appears to be driven by chronic activation of key survival pathways. A limited number of DLBCL cell lines are available, however there are gaps, and specific patient subtypes are not represented. To add to the complexity of clinical diversity, new mutations are being identified in certain treatment-resistant patients. AstraZeneca is interested in innovative proposals to create suitable preclinical models of DLBCL. This is a Reduction-to-Practice Challenge that requires a written proposal and experimental proof-of-concept data (and/or sample delivery). The Challenge has a special award structure. Whether creating a model for DLBCL or a model of acquired resistance to ibrutinib, up to $10,000 will be designated for solutions that highlight novel technologies to generate in vitro cell lines, whereas up to $25,000 will be awarded for submissions that successfully utilize patient-derived tissues.   [更多]

甲基多巴  METHYL DOPA  CAS 555-30-6求购：原料药 甲基多巴的商业化生产工艺，非专利网的文献。有实际完整生产工艺的可以详谈！甲基多巴是一种抗高血压药，为白色或类白色结晶性粉末；无臭。其主要是在中枢转化成甲基去甲肾上腺素。甲基去甲肾上腺素是一种很强的中枢α2受体激动药。用于中、重度或恶性高血压，还有镇静、降低眼压作用。   [更多]

求购 苯磺顺阿曲库铵 原料药 商业化生产工艺！Q2736068151苯磺顺阿曲库铵(cisatracurium besylate)是最新一代肌松剂，广泛应用于气管 插管、肝肾功能障碍、心血管手术等领域。苯磺酸阿曲库铵有4个手性中心，10个同分异构体，分子中含有4个手性中心，其中2个为手性碳，2个为手性氮，顺苯磺阿曲库铵为1R,1'R,2R,2'R异构体。我方需求顺苯磺阿曲库铵大生产合成工艺，要求整个工艺有较好的选择性，反应的收率和产品的纯度较高。我司需要商业化生产工艺而不是 专利网文献，需求真实有效，可提供者可私聊！   [更多]

　　富马酸酮替芬原料工艺，要求工艺成熟，标准EP   [更多]